89 results about "Abdominal aneurysm" patented technology

A heart valve can be replaced using minimally invasive methods which include a sutureless sewing cuff that and a fastener delivery tool that holds the cuff against the patient's tissue while delivering fasteners, two at a time to attach the cuff to the tissue from the inside out. The tool stores a plurality of fasteners. Drawstrings are operated from outside the patient's body and cinch the sewing cuff to the valve body. The cuff is releasably mounted on the tool and the tool holds the cuff against tissue and drives the fastener through the cuff and the tissue before folding over the legs of the fastener whereby secure securement between the cuff and the tissue is assured. At least two rows of staggered fasteners are formed whereby fasteners are located continuously throughout the entire circumference of the cuff. A minimally invasive surgical method is disclosed, and a method and tool are disclosed for repairing abdominal aortic aneurysms in a minimally invasive manner.

A heart valve can be replaced using minimally invasive methods which include a sutureless sewing cuff that and a fastener delivery tool that holds the cuff against the patient's tissue while delivering fasteners to attach the cuff to the tissue from the inside out. The tool stores a plurality of fasteners and is self-contained whereby a fastener is delivered and placed all from inside a vessel. The fasteners are self-forming whereby they do not need an anvil to be formed. Anchor elements are operated from outside the patient's body to cinch a prosthesis to an anchoring cuff of the valve body. The cuff is releasably mounted on the tool and the tool holds the cuff against tissue and drives the fastener through the cuff and the tissue before folding over the legs of the fastener whereby secure securement between the cuff and the tissue is assured. Fasteners are placed and formed whereby fasteners are located continuously throughout the entire circumference of the cuff. A minimally invasive surgical method is disclosed, and a method and tool are disclosed for repairing abdominal aortic aneurysms in a minimally invasive manner. Fasteners that are permanently deformed during the process of attaching the cuff are disclosed as are fasteners that are not permanently deformed during the attaching process.

A stent / graft especially designed to be used in a minimally invasive surgical procedure for treating an abdominal aortic aneurysm (AAA) comprises an innermost tubular structure of a length (L1) formed by braiding a relatively few strands of shape memory alloy wire. The pick and pitch of the braid are such as to provide relative large fenestrations in the tubular wall. A portion of the innermost tubular structure of a length L2<L1 is surrounded by a further braided tubular structure having relatively many strands that occlude the fenestrations of the innermost tubular structure. The composite structure can be stretched to reduce the outer diameter of the stent / graft, allowing it to be drawn into a lumen of a delivery catheter. The catheter can then be advanced through the vascular system to the site of the AAA and then ejected, allowing it to self-expand with the portion L2 bridging the aneurysm. The portion L1>L2 does not block blood flow to the renal arteries while the portion L2 prevents the aneurysm to grown and burst.

A stent graft delivery system includes an internal lead screw assembly within a track of a handle. The internal lead screw assembly is moveable along a major axis of the handle by rotation of a lead screw nut that extends about the handle and is threadably engaged with the threaded portion of the internal lead screw assembly. The lead screw nut is also slidable along the handle while engaged with the internal lead screw assembly. A stent graft system includes a proximal stent adjacent to a bare stent of angled struts joined by proximal and distal apices, wherein the proximal stent is nested within the bare stent.

Disclosed is a method and apparatus for treating bifurcations of the vascular system, such as abdominal aneurysms at the bifurcation of the aorta and iliac arteries. A tubular implant having a first section, a second section and a magnetic connection therebetween is positioned across the bifurcation such that the proximal ends of the first and second sections extends into a first iliac and a second iliac respectively. Deployment catheters are also disclosed.

A thoraco-abdominal branch graft prosthesis includes a lumen main graft component that defines a lumen and at least one main graft wall fenestration. At least one tunnel graft component of the branch graft prosthesis defines at least one tunnel graft fenestration. The tunnel graft component is within the main graft lumen defined by the luminal main graft component. A luminal wall of the tunnel graft component is fixed to the luminal wall of the main graft component. The fenestration of the tunnel graft wall is aligned with the fenestration of the main graft wall. The thoraco-abdominal branch graft prosthesis can be implanted in a patient at a site of a thoraco-abdominal aneurysm.

A bilateral intra-aortic bypass graft and method and apparatus for repairing an abdominal aortic aneurysm includes two tubular grafts which are intraluminally delivered to the aorta and secured to the aorta by the expansion and deformation of two expandable and deformable tubular members.

An endoluminal device for affixation to a wall of a body lumen having a neck region defined by a relatively narrow width and a shoulder region that diverges from the neck region to a relatively wider width. The device comprises a shoulder portion, which may be part of a bulbous portion, having a diameter profile that conforms to the shoulder region, and, in some embodiments, a plurality of affixation members in an area of the device that typically extends from a distal end of the device through the shoulder portion. In one embodiment, the device comprises an endograft for repair of an aneurysm, such as an abdominal aortic aneurysm (AAA). Methods of using the endograft to inhibit continued diametric expansion of the aneurysm and to inhibit endoleak formation and migration of the endograft are also described.

Highly expandable materials have been developed for filling an aneurysm sac and for sealing of endoluminal devices vessel walls. The expandable materials have appropriate chemical and physical properties to withstand radiation, sterilization, or storage in sterilizing solution, without loss of expandable characteristics. The expandable materials may contain protectants, prophylactic, diagnostic, therapeutic, or imaging agents. The expandable materials form a seal that actively conforms to vascular anatomy sealing any leaks that may occur after device implantation. In one embodiment, the technology is used to prevent leaks associated with abdominal aortic aneurysm (AAA) repair, especially for complex AAA repair.

Disclosed is a method and apparatus for treating bifurcations of the vascular system, such as abdominal aneurysms at the bifurcation of the aorta and iliac arteries. A tubular implant having a proximal section, a distal section and a hinged connection therebetween is positioned across the bifurcation such that the proximal section extends into a first iliac and the distal section extends into the second iliac. The proximal and distal iliac sections are both advanced superiorly, causing the implant to fold at the hinge and advance across the aneurysm into the aorta. In one implementation, restraining sleeves are thereafter removed and the implant self expands to place aorta in fluid communication with the first and second iliacs, bypassing the bifurcation. Deployment catheters are also disclosed.

Disclosed are methods for treating endoleaks arising from endovascular repair of abdominal aortic aneurysms. The disclosed methods involve the in situ sealing of endoleaks after placement of an endovascular prostheses in the abdominal aorta. Sealing of endoleaks is achieved by injection of either a biocompatible polymer or prepolymer fluid composition into the endoleak which composition in situ solidifies to seal the leak. Preferably, the biocompatible fluid composition comprises a contrast agent to allow the clinician to visualize the sealing process.

The invention discloses application of FAM210B in the preparation of diagnostic tools for abdominal aortic aneurysm. Experiments prove that FAM210B has expression differences in normal control tissues and abdominal aortic aneurysm tissues; therefore, it is reckoned that FAM210B is a molecular marker for diagnosing abdominal aortic aneurysm. Experiments via in-vitro cultured cells prove that by accelerating the expression of FAM210B, it is possible to inhibit the apoptosis of human aortic smooth muscle cells; therefore, it is reckoned that FAM210B is a drug target for treating abdominal aortic aneurysm. As a new molecular marker for diagnosing and treating abdominal aortic aneurysm, the molecular marker has a promising clinical application prospect.

This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and / or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and / or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and / or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and / or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Disclosed are compositions having one or more statins from two different groups, 1) one or more lipophilic statins and 2) one or more hydrophilic statins. The present invention is also directed towards methods of treating patients with cardiovascular diseases and other vascular diseases, including but not limited to Diabetes Mellitus type I and / or II (DM), coronary artery diseases (CAD), peripheral vascular diseases (PVD), cerebrovascular disease, post myocardial infarctions (post MI), post cerebrovascular accidents (post CVA), Hypertriglyceridemia, Hypercholesterolemia, and abdominal aortic aneurysms (AAA) using the composition of the present invention.

The invention relates to the field of biomedicine, in particular to the application of recombinant P-selectin glycoprotein ligand 1 as a target in preparation of drugs for preventing and / or treating aneurysms. PSGL-1 gene knockout mice are taken as a research object. Compared with wild-type mice, the PSGL-1 gene knockout mice has the characteristics that the incidence of thoracic aortic aneurysm and abdominal aortic aneurysm is significantly reduced, collagen deposition is reduced, elastic fiber breakage and smooth muscle cell degradation are significantly inhibited, infiltration of inflammatory cells is significantly reduced, and expression of inflammatory factors, fibrotic factors and adhesion molecules is significantly inhibited. In addition, the adhesion of peripheral blood mononuclearcells to endothelial cells in the absence of PSGL-1 is also significantly reduced. The invention reveals that the loss of PSGL-1 has the effect of inhibiting aneurysms, and a theoretical basis and clinical basis are provided for the role of PSGL-1 in studying new targets and new strategies for preventing and treating aneurysms.

A method for automatically initializing pose for registration of 2D fluoroscopic abdominal aortic images with a 3D model of an abdominal aorta includes detecting a 2D iliac bifurcation and a 2D renal artery bifurcation from a sequence of 2D fluoroscopic abdominal aortic images, detecting a spinal centerline in a 2D fluoroscopic spine image, providing a 3D iliac bifurcation and a 3D renal artery bifurcation from a 3D image volume of the patient's abdomen, and a 3D spinal centerline from the 3D image volume of the patient's abdomen, and determining pose parameters {x, y, z, θ}, where (x, y) denotes the translation on a table plane, z denotes a depth of the table, and θ is a rotation about the z axis, by minimizing a cost function of the 2D and 3D iliac bifurcations, the 2D and 3D renal artery bifurcation, and the 2D and 3D spinal centerlines.

This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and / or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and / or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

The invention discloses a vascular covered stent with anti-thrombus / anti-tumor function and a preparation method thereof, the vascular covered stent is composed of a metal stent and a fabric covered film carrying drugs inside and outside respectively, and an outer layer of the covered film is provided with a drug bag interlayer. The covered film is loaded with an anti-thrombus drug through an inner layer and loaded with an anti-tumor drug through an outer layer drug bag interlayer; a covalent cross-linking technology is used; antithrombotic coating is carried out on the inner layer of the covered film; the inner layer of the covered film can resist thrombus and quickly endothelialize; curcumin and metformin microspheres are carried on the cavity interlayer of the outer layer of the covered film, anti-tumor treatment can be carried out on the aortic aneurysm, long-term slow release of medicine is achieved, restenosis is effectively prevented, tumor growth is inhibited, the risk of vascular rupture is reduced, and the covered stent is particularly suitable for abdominal aortic aneurysm patients.

The invention discloses an application of Adamtsl3 as a diagnosis and treatment marker for abdominal aortic aneurysm, and also discloses a reagent and a kit for detecting Adamtsl3. The invention further discloses a method and a medicine for treating abdominal aortic aneurysm. The above research achievements provide a new strategy and thought for clinically treating abdominal aortic aneurysm.

The invention discloses a biology marker for making diagnosis and giving treatment on abdominal aortic aneurysm. The biology marker is OTUB2. QPCR experiments prove that the OTUB2 has difference expression in patients suffering from abdominal aortic aneurysm, in order to further verify the relevance of the OTUB2 and the abdominal aortic aneurysm, an AAA cell model is constructed, so that the viewpoint that interference of OTUB2 expression can reverse damage effects of Angiotensin II on cells can be proved, and the OTUB2 can be the biology marker for making diagnosis and giving treatment on abdominal aortic aneurysm. The research findings provide a new method and strategy for clinical diagnosis or treatment of the abdominal aortic aneurysm.

The invention provides abdominal aortic aneurysm animal models and a building method thereof. According to the abdominal aortic aneurysm animal models, erythropoietin is used as an inducer. The abdominal aortic aneurysm animal models are short in model building time and high in tumor formation rate, no surgical operations are needed, only intraperitoneal injection is needed, trauma to animals is little, the technical requirements of experimenters are low, the operability is high, no mice with specific genes knocked out are needed, and the abdominal aortic aneurysm animal models can be achievedwith the wild-type mice (animals).

The present invention provides a package comprising an aortoiliac artery graft and a record of a measured pressurized diameter of the aortoiliac artery graft, which measurement has been determined ex vivo under a pressure. A method of processing an aortoiliac artery graft is also provided. The processing method comprises subjecting an aortoiliac artery to a pressure ex vivo, and determining a measured pressurized diameter of the aortoiliac artery under the pressure. A method of treating abdominal aortic aneurysm, infected aortoiliac endograft or a traumatically damaged abdominal aorta or an iliac artery in a patient is further provided. The treatment method comprises anastomosing a processed aortoiliac artery graft with an aorta of the patient on the proximal end and the iliac or femoral arteries on the distal end, wherein a measured pressurized diameter of the processed aortoiliac artery graft has been determined ex vivo under a pressure.

The invention belongs to the field of image data processing, particularly relates to a blood vessel registration method, system and device for an intravascular aneurysm operation, and aims at solvingthe problems that a registration image generated by an existing image registration technology is fuzzy, long in consumed time and much in interference. The method comprises the following steps: converting an acquired CTA image into an aorta blood vessel three-dimensional image, further converting the aorta blood vessel three-dimensional image into an aorta blood vessel two-dimensional image, converting a DSA image into an aorta blood vessel binary image, and obtaining a registered image through a blood vessel registration network based on deep learning, wherein the blood vessel registration network is constructed based on the regression device sub-network, the space transformation sub-network and the re-sampling sub-network. According to the invention, the problem that the DSA image is blurred in the operation can be solved, the abdominal aortic aneurysm position can be found more quickly and accurately in the current X-ray transmission image, and the requirement for assisting a doctorin the intravascular aneurysm repair operation in real time can be met.

The invention relates to application of a LKB1 gene in preparation of anti-abdominal-aortic-aneurysm drugs. According to the application of the LKB1 gene in preparation of the anti-abdominal-aortic-aneurysm drugs, important role of the LKB1 gene in regulating expression of matrix metalloproteinase-2 in smooth muscles is disclosed by constructing gene knockout mice with LKB1 gene specifically knocked-out in smooth muscles; and significantly increased incidence of abdominal aortic aneurysm in the LKB1-gene-knockout mice is discovered by constructing abdominal aortic aneurysm models in mice by performing subcutaneous infusion of angiotensin II (Ang II). In addition, lentiviruses with the LKB1 gene are further prepared by the invention. Being injected into tail veins of mice, the lentiviruseswith the LKB1 gene are capable of significantly reducing incidence of abdominal aortic aneurysm in the mice. The anti-abdominal-aortic-aneurysm drugs prepared or screened by using the LKB1 gene as a target according to the invention are of great significance to treatment on abdominal aortic aneurysm.

The invention discloses (E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-benzyl-2-acrylamide (AG490 for short) of the following formula in the prevention and treatment of abdominal aortic aneurysm the use of. In the CaCl2-induced abdominal aortic aneurysm model, AG490 can not only prevent the occurrence of abdominal aortic aneurysm, but also prevent the progressive development of abdominal aortic aneurysm; AG490 can significantly inhibit the expression and activity of matrix metalloproteinases, and alleviate the effect of this proteolytic enzyme on the abdominal aortic aneurysm model. The destruction and degradation of vascular tissue maintains the relative integrity of vascular structure; AG490 can reduce the expression of vascular α-smooth muscle actin (α-SMA) and reduce the deposition of vascular adventitial collagen.

The invention relates to a covered stent system. The covered stent system comprises a covered stent and a diameter restraining piece arranged on the covered stent. The diameter restraining piece is used for restraining the covered stent and can release the covered stent; the inner diameter of the covered stent after being bound is smaller than the inner diameter of the covered stent after being released, and the covered stent after being bound is provided with a through inner cavity. Due to the fact that the diameter restraining piece can restrain the covered stent, after the covered stent system is guided into an abdominal aortic aneurysm diseased region, the covered stent is not attached to a blood vessel; the covered stent can move between the near end and the far end after being bound by the diameter restraining piece until the first window of the covered stent faces the celiac trunk artery and / or the superior mesenteric artery and the second window of the covered stent faces the renal artery, the covered stent can still be adjusted in the process that the branch covered stent is guided in to establish a blood flow channel, and accurate positioning is facilitated; the bound covered stent is provided with a through inner cavity, blood flow can smoothly pass through the through inner cavity, and blood flow perfusion of the inner cavity of the covered stent is guaranteed.

A system includes a probe configured to transmit ultrasound signals directed to a target blood vessel and receive echo information associated with the transmitted ultrasound signals. The system also includes at least one processing device configured to process the received echo information and generating a three-dimensional ultrasound image of the target blood vessel; obtain a three-dimensional vascular model corresponding to the target blood vessel; identify a best-fit of the three-dimensional vascular model onto the three-dimensional target image; store the best fit of the three-dimensional vascular model as a segmentation result; and calculate, based on the segmentation result, measurements for the target blood vessel.

The invention relates to a modular stent with branches for treating thoracoabdominal aortic aneurysm, and belongs to the technical field of medical instruments. The stent is a covered stent and comprises a descending aorta region near-end anchoring module, a visceral artery region branch graft module and an abdominal aorta region far-end anchoring module which are communicated in sequence; the number of the descending aorta area near-end anchoring module is at least one. The invention provides a modular endovascular graft with branches for treating thoracico-abdominal aortic aneurysm of Asian people. Through modularization and different combination modes, anatomical structures of various thoracico-abdominal aortic aneurysms can be adapted, and the time required by customization can be effectively avoided; visceral arteries and renal arteries can be reconstructed through branches; sufficient friction force is provided for graft anchoring and bridging through combined anchoring, branch selection is facilitated through a guide wire guiding area, and operation difficulty and the time are reduced. Therefore, the thoracico-abdominal aortic aneurysm is effectively treated, the operation time is shortened, and adverse reactions of contrast agents are reduced.

The invention relates to the field of biomedicine, in particular to the application of P-selectin glycoprotein ligand-1 as a target in the preparation of drugs for preventing and / or treating aneurysms. The present invention takes PSGL‑1 gene knockout mice as research objects, and by comparing with wild-type mice, it is found that the incidence of thoracic aortic aneurysm and abdominal aortic aneurysm in the PSGL‑1 gene knockout group mice are significantly reduced, collagen The deposition becomes less, the breakage of elastic fibers and the degradation of smooth muscle cells are significantly inhibited, and the infiltration of inflammatory cells is significantly reduced, and the expression of inflammatory factors, fibrosis factors and adhesion molecules is significantly inhibited. In addition, the adhesion of peripheral blood mononuclear cells to endothelial cells was significantly reduced in PSGL-1-deficient PBMCs. The present invention reveals that the deletion of PSGL-1 has the effect of inhibiting aneurysms, and provides a theoretical basis and clinical basis for the role of PSGL-1 in the study of new targets and new strategies for preventing and treating aneurysms.